Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | HS-110 |
Trade Name | |
Synonyms | Viagenpumatucel-L|AD100-gp96-Ig-HLA A1 |
Drug Descriptions |
HS-110 (viagenpumatucel-L) is a tumor cell vaccine comprised of irradiated tumor cells expressing recombinant gp96-Ig, which is secreted and induces an immune response to endogenous tumor cells (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C61073 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cyclophosphamide + HS-110 | Cyclophosphamide HS-110 | 0 | 1 |
HS-110 | HS-110 | 0 | 1 |
HS-110 + HS-130 | HS-110 HS-130 | 0 | 1 |
HS-110 + Nivolumab | HS-110 Nivolumab | 0 | 0 |